Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28452075 | 0.86 | SLC6A4 (0.45) | GAAKMT2AL3MBTL1EGLN1HTR1A | |
| SCHEMBL14021979 | 0.85 | KMT2A (0.44) | KMT2ASMN1; SMN2ACHE | |
| SCHEMBL446449 | 0.84 | AR (0.47) | GAAKMT2AL3MBTL1HTR1AHTR3A | |
| SCHEMBL30354890 | 0.81 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2LRRK2 | |
| SCHEMBL4797567 | 0.81 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2LRRK2 | |
| SCHEMBL2029286 | 0.81 | ALDH1A1 (0.53) | GAARAB9AKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4797564 | 0.81 | LRRK2 (0.38) | GAANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL8484975 | 0.80 | NTRK1 (0.48) | GAASMN1; SMN2HTR1AHTR3A | |
| SCHEMBL14021916 | 0.79 | ALDH1A1 (0.55) | GAAKMT2ASMN1; SMN2 | |
| SCHEMBL4950654 | 0.79 | HTR1A (0.50) | GAANPC1RAB9AKMT2ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-7501512-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501512-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | MILLER SCOTT | 2008-10-30 | — | — | US | disclosed |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | MILLER SCOTT | 2008-10-30 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | GAA 3315/4885NPC1 3232/4885RAB9A 1346/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | GAA 3315/4885NPC1 3232/4885RAB9A 1346/4885 |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | BRAF, RAF1, MAP2K2 | GAA 3305/4885NPC1 2562/4885RAB9A 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.